In the Clinic
The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.
In the Lab
Researchers are developing uses for a drug that could benefit many people with lung cancer.
In the Clinic
A new treatment is approved for an especially aggressive kind of colorectal cancer.
In the Lab
A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.
Profile
David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.
Honors
Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.
